Radiopharm TheranosticsASX:RAD -5.00% Gross Margin % is 12.01% as of Jun. 2025, which is 1022% above its 10-year median of 1.07. The stock has 5 warning signs investors should review. Among 738 Biotechnology companies, Radiopharm Theranostics ranks worse than 92.01% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Radiopharm Theranostics had a gross margin of 12.01% for the quarter that ended in Jun. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Radiopharm Theranostics Gross Margin % Related Terms
Radiopharm Theranostics Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RAD vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Radiopharm Theranostics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiopharm Theranostics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Radiopharm Theranostics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Radiopharm Theranostics (ASX:RAD) has a Gross Margin % of 12.01% as of Jun. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Radiopharm Theranostics and its competitors. This is 1022% above median its historical median of 1.07. Over the past decade, Radiopharm Theranostics' Gross Margin % has ranged from 1.07 to 1.07. According to the industry distribution chart, Radiopharm Theranostics ranks #679 out of 738 companies in the Biotechnology industry, placing it in the top 92%.
Is Radiopharm Theranostics' Gross Margin % too high?
Radiopharm Theranostics' current Gross Margin % of 12.01% is 1022% above median its 10-year median of 1.07. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 1.07. The Biotechnology industry median Gross Margin % is 60.94. Radiopharm Theranostics' value of 12.01% is 80.3% below this industry median. Based on the distribution chart, Radiopharm Theranostics ranks #679 out of 738 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Radiopharm Theranostics' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #679 out of 738 companies for Gross Margin %. This places Radiopharm Theranostics in the lower half of its industry. The industry median Gross Margin % is 60.94. Radiopharm Theranostics' value of 12.01% is 80.3% below this benchmark. Historically, Radiopharm Theranostics' own Gross Margin % has ranged from 1.07 to 1.07 over the past decade. While the company's 10-year median is 1.07 vs. the industry median of 60.94, Radiopharm Theranostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radiopharm Theranostics's current Gross Margin % of 12.01% is 80.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Radiopharm Theranostics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiopharm Theranostics's current Gross Margin % is 12.01%, which is 1022% above median its own 10-year median of 1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Gross Margin % of 12.01%. The current Gross Margin % is 12.01%, which is 1022% above median its 10-year median of 1.07 and 80.3% below the Biotechnology industry median of 60.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Gross Margin % is 12.01% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RAD has been successfully added to your